💧

Haven’t read the first part yet? You can find it here 📬

In the first part, we outlined the fundamentals of CRISPR-Cas9 and the pioneers who were the first to bring this technology to the public markets. Now, we take a look at the next wave of players and summarize the clinical results from 2023–2025.

The Landscape of the Gene Editing Industry – New Players

The story doesn’t end with the first pioneering companies. Soon after, new firms emerged — some focusing on therapies for additional diseases, and others advancing next-generation CRISPR technologies.

Beam Therapeutics — Base Editing: Less Cutting, More Meaning

Beam Therapeutics is a company founded in 2017 by scientists from MIT and Harvard, including the eminent chemist David Liu, the inventor of base editing. Beam’s mission is to apply base editors in therapy—that is, to modify single nucleotide pairs without cutting both strands of DNA. Base editors are fusion proteins composed of a “crippled” Cas nuclease (which binds DNA at a specified site but does not cleave it) and a base-modifying enzyme (e.g., a deaminase that converts one base into another). As a result, one can make, for example, a C→T or A→G substitution at a chosen site in the genome[8]. Although small, such a change can be sufficient to repair many disease-causing mutations. Crucially, no dangerous double-strand break is created, which reduces the risk of adverse effects (e.g., chromosomal rearrangements or oncogene activation)[8]. Beam Therapeutics is developing an entire platform of different editors (cytosine, adenine, etc.) to tailor them to various diseases.

Like other companies, Beam first targeted hemoglobin-related blood disorders. Its BEAM-101 program focuses on sickle cell disease—but instead of cutting the BCL11A gene as CRISPR Tx or Editas do, the base editor changes a single DNA letter to activate the fetal hemoglobin gene. The end goal is the same: raise HbF levels and eliminate disease symptoms[8][64]. In January 2024, Beam dosed the first patient with BEAM-101. In 2025, the company presented initial clinical data (sustained HbF increase with no new safety signals) and obtained RMAT status from the FDA for BEAM-101 (August 2025), which accelerates the regulatory pathway. It is worth noting that a competing company, Sangamo Therapeutics, is testing an analogous HbF-boosting method using zinc-finger nucleases—its earlier results were mixed. If Beam demonstrates a clear effect with minimal complications, it may outpace that older technology.

Beam is also active in oncology. In 2022, a team in the UK (Great Ormond Street Hospital) described a case of a teenage patient with refractory T-cell leukemia who received CAR-T lymphocytes modified using base editing. It was the first therapeutic use of base editing—thanks to it, the donor T cells were altered so that they would not attack each other or be rejected, while targeting the CD7 marker on leukemia cells [65][66]. The patient (Alyssa) achieved remission and was then able to undergo a definitive bone marrow transplant, which saved her life [65][67].. This case study demonstrated the power of base editing to create “enhanced” cells to fight cancer. Beam Therapeutics collaborates with these clinicians and, in parallel, has initiated its own clinical trial, BEAM-201—an allogeneic anti-CD7 CAR-T for T-cell leukemia (targeting CD7, as in Alyssa’s case). The product includes several edits (e.g., removal of TCRs so the cells do not attack the patient, and receptor edits to avoid rejection and self-destruction)[68]. The first preliminary ASH 2024 data for BEAM-201 indicated activity signals for this multiply edited, allogeneic anti-CD7 CAR-T—enrollment and updates continue in 2025.

Beam is also developing in vivo therapies. Here, however, instead of CRISPR-Cas9, it uses base editors delivered via LNPs. The company has had programs in dyslipidemias (lowering cholesterol by editing PCSK9 or ANGPTL3), but Verve Therapeutics has pulled ahead in this area (more on Verve below). Beam has, however, signed a major partnership with Pfizer—to apply base editors in the liver, muscle, and CNS. This implies potential in areas such as Duchenne muscular dystrophy or CNS diseases, though these are still in the preclinical stage.

Strengths of Beam: As a pioneer of base editing, the company possesses CRISPR 2.0 technology that can solve some of the pain points of the classical approach. Base editors enable correction of point mutations without introducing DNA breaks—an enormous advantage where a subtle fix suffices instead of cutting out a gene. They can also target genes where a cut could be lethal but a small change is enough (e.g., converting a pathogenic codon into a stop codon). Beam has strong scientific backing—rooted in Liu’s work—with key patents in the field. It is therefore a dominant player in base editing and a potential technology provider to others (several firms have taken licenses). In addition, Beam has strategically broadened its portfolio: it operates in genetic blood disorders, oncology, and cardiovascular indications (in collaboration with Verve), and it has a major deal with Pfizer—providing diversification. Financially, Beam amassed substantial funds during the boom (its IPO and follow-on offerings brought in hundreds of millions of dollars), which still serves as a cushion. If any program proves successful, Beam’s value could rise quickly.

Weaknesses of Beam: The biggest drawback is the lack of human efficacy data—Beam is only just beginning patient trials. Others already have therapies on the market or in advanced stages, while Beam must demonstrate in practice that base editing offers advantages beyond theory. There is also the safety question—although there is no double-strand break, base editors can cause unintended base changes within a certain DNA “window” (biochemical off-targets—they may alter similar sequences or cause mosaicism). Work is ongoing to improve enzyme specificity, but only clinical trials will show how clean these edits are. Furthermore, base editors are limited to certain substitutions (e.g., C→T), meaning not every mutation can be repaired with this method. In sickle cell disease the goal is not a specific mutation but gene silencing (which base editing achieves indirectly), so it fits here. In other diseases, however, the editor may be powerless if a more complex fix is required—prime editing (a competing technology) may be better in such cases.

In sum, Beam is valuable but still a “prove-it” company. The next 1–2 years with first patient results will be critical. If strong effects emerge (e.g., durable cures in additional SCD patients or an effective CAR-T in T-cell leukemia), investor attention and capital may shift toward Beam as the next genetics star.

Caribou – universal CAR-T

Caribou Biosciences is a Berkeley, California–based company co-founded by Jennifer Doudna in 2011 (initially as a research tool company) and later transformed into a therapeutics firm. Caribou stands out for its proprietary modifications to the CRISPR system—it developed its own chimeric guides (chRDNA) designed to increase editing precision and reduce off-target risk. The company has focused primarily on cancer immunotherapy, developing allogeneic (donor-derived) CAR-T cells similar to CRISPR Therapeutics, but leveraging its gene-editing technology to produce better cells.

Caribou’s lead candidate is CB-010—CAR-T lymphocytes targeting CD19 (expressed on B-cell lymphomas) with two edits: (1) deletion of the TRAC gene (the T-cell receptor) to prevent donor cells from attacking the recipient’s body, and (2) PD-1 knockout in the lymphocytes to prevent their “shutdown” by tumor signals [70]. This second edit is novel—PD-1is an inhibitory molecule often exploited by tumors to suppress immune attack. Standard autologous CAR-T cells can still succumb to this mechanism, but in Caribou’s product PD-1 “doesn’t work,” allowing the cells to remain active longer. Phase 1 results (16 treated patients with refractory non-Hodgkin lymphomas) were very promising: 15 of 16 patients responded to treatment, including 7 who achieved complete remission lasting ≥6 months [70][71]. In one patient, remission lasted over 24 months (two-year follow-up)[72]—the longest documented durability to date for an allogeneic CAR-T therapy. These data led the FDA to grant RMAT, Fast Track, and orphan drug designations to CB-010, which should accelerate its development [73][74]. Caribou announced plans to skip Phase 2 and proceed directly to a pivotal Phase 3, aiming to start by the end of 2024 [75]. Meanwhile, enrollment of ~30 additional patients continues in Phase 1 to select the optimal dose for Phase 3 [76]. It’s an aggressive but exciting strategy—if successful, CB-010 could become the first off-the-shelf CAR-T therapy for lymphomas, significantly simplifying and speeding up treatment (current autologous CAR-T requires individualized manufacturing over several weeks for each patient).

Caribou isn’t stopping at one product. In 2023 the company launched two additional Phase 1 trials: CB-011—a CAR-T targeting BCMA in multiple myeloma (here, in addition to standard edits, an MHC class I modification was added so the cells evade the recipient’s immune response) and CB-012—a CAR-T targeting CLL-1 on AML leukemia cells [77]. Both programs employ advanced gene edits and aim to improve outcomes in hard-to-treat cancers (myeloma and AML). Results will take time—initial safety readouts are expected in 2025.

Strengths of Caribou: The company has some of the best clinical results in off-the-shelf CAR-T—remissions in nearly half of patients at ≥6 months are comparable to autologous CAR-T and better than most experimental allogeneic CAR-T products, which often produced only short-lived responses [32][78]. The PD-1 edit appears to work, an important proof that multi-gene engineering can translate into better therapies. Caribou also has a strong IP position—its chRDNA(hybrid RNA-DNA guides) allow for more precise DNA cutting with a lower error risk, which can be licensed or provide a safety advantage. Its pipeline is thoughtfully sequenced: starting with lymphomas (easier CAR-T targets) to build know-how, then moving into increasingly difficult cancers. The company has also expressed ambitions beyond oncology, having signaled early work on in vivo editing for genetic diseases.

Weaknesses of Caribou: Like any cell-therapy company, it faces challenges in scaling manufacturing and controlling costs. Although allogeneic CAR-T is intended to be cheaper than individualized products, it still involves complex cell-engineering processes requiring standardization. Competition in immunotherapy is intense: other companies are developing universal CAR-T (e.g., Allogene Therapeutics using TALEN technology), as well as newer modalities like NK-cell or TCR-based therapies. Caribou must maintain a technological edge—planning a Phase 3 is encouraging, but the FDA could still request additional Phase 2 data if concerns arise. Long-term safety is also crucial in CAR-T: cytokine release syndrome, opportunistic infections, etc., can occur—Caribou has recorded such events (as in any immunotherapy), e.g., infections in some patients due to temporary immunosuppression [67][80]. These effects are serious but acceptable in life-threatening diseases. To surpass autologous CAR-T, Caribou must demonstrate at least comparable efficacy with better access/cost. Finally, financially Caribou is relatively small—the funds from its IPO can be consumed within 1–2 years of intensive trials. It may need a partner (e.g., for global commercialization if approved) or additional equity raises, which introduces uncertainty for investors.

Bottom line: Caribou has done an excellent job so far and is often cited as a “dark horse” of the CRISPR race—a company that could achieve major success in the oncology niche.

The rest of the field: from “holy grail” to “lipid reset”

Prime Medicine was founded in 2021 by David Liu and colleagues to develop prime editing, a next-generation form of genome engineering. Although younger and not yet in the clinic, the company deserves attention because prime editingis often regarded as the “holy grail” of gene editing. This method combines a modified Cas9 (which cuts only one DNA strand) with a reverse transcriptase enzyme, enabling the precise insertion, deletion, or replacement of virtually any DNA sequence at a chosen genomic site [9]. In theory, it can correct mutations that neither base editing nor classical CRISPR can fix—such as large deletions or insertions.

Prime Medicine went public in 2022, raising capital to support its research programs. So far, its work remains preclinical, as the company selects its first therapeutic targets. Nevertheless, 2025 brought the first real-world glimpse of prime editing’s potential: physicians in the United Kingdom reported the case of a teenage patient with a rare DNA-dependent protein kinase deficiency, whose own T cells were edited ex vivo using prime editing to repair the mutation [9][10]. The results were positive—his immune function improved [10]. This marks the first evidence that prime editing can work not only in vitro, but also in living human tissue.

In the coming years, Prime Medicine plans to advance its first therapies into clinical trials. Despite not yet having any approved products or human data, the company was valued at approximately USD 1.1 billion in 2025 [43] — a reflection of the transformative potential investors see in this “CRISPR 3.0” platform.

Verve Therapeutics aims to prevent cardiovascular disease by editing genes in otherwise healthy but at-risk individuals. Verve focuses on genes that regulate cholesterol and lipid levels. Its first therapy, VERVE-101, uses a base editor delivered in LNP nanoparticles to the liver to knock out the PCSK9 gene. People with naturally inactive PCSK9 have very low levels of “bad” LDL cholesterol and are essentially protected against heart attacks. Verve reasoned that instead of daily statins or periodic antibody injections, one could lower LDL once and for all through gene editing. In 2022, the company began a Phase 1 study in New Zealand and the UK in patients with genetically driven hypercholesterolemia (HeFH). The first results, presented in 2023, showed that in three patients who received ascending doses, LDL fell by 40–55%, and this effect persisted for at least half a year [81]—more than is typically achieved with statins [82]. At the same time, plasma PCSK9 levels nearly disappeared—evidence that the gene edit worked [83]. Unfortunately, the study also saw serious incidents: two participants experienced cardiovascular events (including one death), but analysis indicated these stemmed from pre-existing advanced coronary disease[84]. One person may have had a therapy-related adverse effect (cardiac arrhythmia), though this is uncertain[84]. These events prompted caution from the U.S. FDA, which initially withheld permission for U.S. sites to join the trial, requesting additional safety data (especially regarding any potential editing in germ cells) [85]. Verve supplied those data, and in October 2023 the FDA lifted the hold, allowing U.S. participation [86]. The company plans in H2 2025 to start a placebo-controlled Phase 2 for VERVE-102, after completing dose escalation in Heart-2 and obtaining regulatory approvals.
What’s more, Verve is developing a second editor (VERVE-201) that knocks out ANGPTL3, which lowers triglycerides and other lipids. Both genes (PCSK9, ANGPTL3) target relatively small patient subsets (primarily those with familial mutations), but Verve is thinking ahead: in the future, once safety is proven, such one-and-done therapies might be used prophylactically in a broader high-risk population. That scenario is distant but not impossible—Fyodor Urnov draws an analogy: statins were first tested in patients with genetic hypercholesterolemia, then in those with heart disease, and finally became a mass preventive therapy [87][88].

Verve and CRISPR Tx are taking similar paths. In 2023, CRISPR Therapeutics launched its own in vivo programs editing ANGPTL3 (CTX310) and Lp(a) (CTX320). In September 2025, the company presented first data—a single dose of CTX310 strongly reduced ANGPTL3 and lipids, and CTX320 lowered Lp(a).

In the future, this could unlock a huge market: a single treatment that simplifies control of cholesterol or other risk factors, potentially for millions of people [91][92]. Of course, the precondition is demonstrating long-term safety—the bar is highest here because we intervene in people who might otherwise live for decades and who are relatively healthy at the time of therapy.

Sangamo Therapeutics and Cellectis—worth mentioning as pioneers of the previous generation, still active today.

Sangamo (USA) has developed zinc-finger nucleases (ZFNs) since the 1990s. It conducted some of the first human gene-editing trials—for example, in 2017 it delivered ZFNs directly to the liver of patients with Hunter syndrome (MPS II), attempting to repair the IDS gene. Unfortunately, the therapy did not yield meaningful improvement (enzyme levels did not rise significantly). Sangamo also tested gene editing in T cells to treat HIV (modifying the CCR5 receptor, analogous to what He Jiankui did in embryos)—some patients temporarily suppressed the virus, but it found other ways to persist. Sangamo has since shifted toward using gene editing to create regulatory T cells (CAR-Treg) to dampen autoimmune disease and in transplantation. It also has partnerships (e.g., with Pfizer on PCSK9 editing, though Pfizer has now prioritized base editing with Beam). With the oldest technology, Sangamo suffered after CRISPR’s rise—its market cap fell sharply, and the company is fighting for niches where it can remain competitive (e.g., epigenetic editing instead of direct DNA cuts).

Cellectis, meanwhile, is a pioneer of TALEN. Its editing method underpinned the first autologous CAR-T therapies (developed in Europe for a young leukemia patient as early as 2015). Today, Cellectis, in collaboration with U.S. firm Allogene, is developing allogeneic CAR-T for lymphomas and myeloma, using TALEN to knock out receptors. Allogene’s clinical results have been moderate—there were responses, but also issues (e.g., in 2021 the FDA placed a hold due to chromosomal aberrations in modified cells, which were ultimately deemed benign clonal events). Cellectisalso has its own Phase 1 CAR-T programs. Overall, however, TALEN is more labor-intensive, and in the era of CRISPR/base editing/TCR, it faces the challenge of proving its continuing value.

Note on Partnerships

The gene-editing industry runs on partnerships with Big Pharma. Vertex backs CRISPR Therapeutics, Regeneronsupports Intellia, and Pfizer has teamed up with Beam (having previously partnered with Sangamo). Novartis invested early in several startups, while Bristol Myers Squibb (BMS) collaborated with Editas. Eli Lilly has partnered with both Precision BioSciences and Verve Therapeutics, signaling an interest in expanding into cardiometabolic targets. Meanwhile, institutional investors such as ARK Invest and BlackRock have built significant exposure to the space.

These alliances provide capital, know-how, and access to manufacturing infrastructure, but they also come with trade-offs — reduced autonomy, rights of first refusal, and commercial dependencies that can narrow strategic flexibility.

As scientific risk declines, the spotlight shifts to execution quality and corporate governance. Inefficient management can undervalue a company relative to its scientific merit, or even erode liquidity, leaving it in a weakened negotiating position — a setup that often precedes unfavorable takeovers.

Conclusion — Part II

In Part I, we saw how Editas, Intellia, and CRISPR Therapeutics opened the era of CRISPR commercialization. By now, one thing is clear: CRISPR is no longer a promise — it’s a bill — clinically payable, but still commercially negotiated. The next 24 months will determine who truly has the technology, and who merely has a presentation. Some will learn the gravity of capital, others — the scale of manufacturing and the patience of regulators.

With that, we conclude the mapping of the second wave of players. Part III (final) will no longer ask who holds the technology, but rather where the field stands clinically in 2023–2025, what approval milestones lie ahead, and what scaling, cost, and regulatory barriers remain. We’ll also ask the key question: who can realistically turn CRISPR from a promise into a fully-fledged market for precision medicine.

To be continued… and with it comes ✨

🧬 The Gene Editing Revolution — Part III (Final)
🦄💎 The Opening of the Unicorn Vault

🦄💎 Unicorn Vault

• 🧬

• 🧧

📚 Selected References

· U.S. Food and Drug Administration – press release on the approval of the first CRISPR therapy (Casgevy) for sickle cell disease [2][3].

· Innovative Genomics Institute, CRISPR Clinical Trials: A 2024 Update – overview of ongoing CRISPR trials, including results in SCD/TDT, ATTR, HAE, and CAR-T [111][48][53][70].

· STAT News, Jason Mast, The CRISPR companies are not OK (2025) – analysis of the sector’s challenges and the gap between scientific breakthroughs and financial success [1][40].

· Nanalyze, When Will Gene Editing Stocks Finally Take Off? (2025) – examination of correlations and valuations across gene-editing companies [109][43].

· Nature News, Heidi Ledford, World first: ultra-powerful CRISPR treatment trialled in a person (2025) – coverage of the first use of prime editing in a human patient [9][10].

· The Guardian, Ian Sample, Chinese scientist who edited babies’ genes jailed for three years(2019) – report on He Jiankui’s case and its ethical fallout [11][12].

· Fierce Biotech, James Waldron, Graphite’s hopes for sickle cell ‘cure’ blunted after first patient dosed experiences serious event (2023) – report on Graphite Bio’s halted trial [103].

· U.S. FDA – background on indications and mechanism of action for Casgevy and the parallel lentiviral therapy (Lyfgenia) [2][3].

(Sources: high-reputation English-language publications with up-to-date scientific and financial data as of August 2025.)

📖 References

[1] [40] [59] The CRISPR gene editing revolution loses its mojo. STAT News. (Feb 2025). Link

[2] [3] [4] [5] [18] [116] FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. FDA Press Release. (Dec 2023). Link

[6] [7] CRISPR Illustration. National Institute of General Medical Sciences. Link

[8] [13]–[15], [19]–[21], [22]–[39], [41], [44]–[49], [50]–[58], [61]–[63], [64]–[111] CRISPR Clinical Trials: A 2024 Update. Innovative Genomics Institute. (2024). Link

[9] [10] Ledford H. World first: ultra-powerful CRISPR treatment trialled in a person. Nature. (2025). Link

[11] [12] Sample I. Chinese scientist who edited babies’ genes jailed for three years. The Guardian. (Dec 2019). Link

[42] [43] [79] [109] When Will Gene Editing Stocks Finally Take Off? Nanalyze. (Jul 2025). Link

[60] Editas, changing course again, looks to partner lead CRISPR therapy. BioPharma Dive. (2024). Link

[103]–[106] Waldron J. Graphite’s hopes for sickle cell ‘cure’ blunted after first patient dosed experiences serious event.Fierce Biotech. (2023). Link

[110] Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data. ASCO Annual Meeting. (2024). Link

[111] Exploring FDG PET + MRI for multiple myeloma staging. J Clin Oncol. ASCO (2024). Link

[112] [113] [115] Caribou Biosciences Reports Q2 2025 Results and Pipeline Update. Caribou Investor Relations. (Aug 2025). Link

[114] CB-010 (ANTLER trial) clinical update. J Clin Oncol. ASCO (2024). Link

[117] Prime Medicine announces breakthrough clinical data (PM359, CGD). Prime Medicine Investor Relations. (2025). Link

🐣🐣

Introduction

Few technologies have reshaped modern biomedicine as profoundly as gene editing. By rewriting DNA with unprecedented precision, scientists can now imagine cures that strike at the very root of genetic disorders, train immune cells to fight cancer, and even reduce the risks of widespread chronic diseases. At the heart of this revolution is CRISPR–Cas9. In 2020, it won the Nobel Prize in Chemistry, with the Committee declaring that it “may realize the dream of curing inherited diseases” [1]. Since then, billions of dollars have flowed into the field, fueling a wave of biotech startups and established players, all racing to turn that dream into clinical reality.

By the second half of 2025, the CRISPR revolution has entered a more mature phase: the first therapies have been approved and are reaching patients [2][3], while others are advancing through late-stage trials (SCD/TDT, ATTR, HAE, oncology). In this piece, we’ll map out the foundations, milestones, leading companies, and the realities of commercialization — with a focus on CRISPR Therapeutics, Intellia, and Editas.

What is Gene Editing and the CRISPR–Cas9 Technology?

Gene editing is the precise manipulation of DNA — adding, removing, or altering fragments of genes. Scientists have experimented with genetic engineering for decades, but earlier methods were costly and technically complex. The breakthrough came in 2012, when Jennifer Doudna and Emmanuelle Charpentier introduced CRISPR–Cas9.

The CRISPR–Cas9 mechanism is borrowed from a natural defense system bacteria use against viruses. Researchers managed to reprogram it so that it cuts DNA at a precisely chosen spot. Think of it as molecular scissors with a built-in GPS: the Cas9 enzyme slices the DNA at the exact location indicated by a short guide RNA (designed to match the target sequence) [4][5]. Once the cut is made, the cell’s natural repair machinery kicks in, rejoining the broken strands. That’s the critical moment when scientists can introduce changes — disabling a faulty gene or inserting a correct version of DNA.

Why Did CRISPR Spark Such Strong Reactions? 🤯🔬

Compared to earlier gene-editing tools like zinc-finger nucleases (ZFNs) or TALENs, the CRISPR–Cas9 system proved to be simpler, cheaper, and far more versatile. Designing the guide RNA for a chosen gene can be done entirely on a computer, which meant labs around the world could quickly adopt and apply the technology.

CRISPR makes it possible to edit virtually any gene in almost any organism — from human cells, to lab animals, to crop plants. The medical applications are especially promising: repairing mutations responsible for genetic disorders (such as sickle cell anemia or cystic fibrosis), disabling genes that allow viruses like HIV to persist in the body, or reprogramming immune cells to attack cancer. 🌱🧪

From CRISPR to CRISPR 2.0 🚀🧬

Still, CRISPR–Cas9 is not the only gene-editing tool — it’s more like the first generation of a fast-evolving toolkit. What scientists now call CRISPR 2.0 includes base editing and prime editing, both designed to make the process more precise and safer.

Base editors, developed by David Liu at Harvard, allow single-letter changes in DNA without cutting the double helix. That makes it possible to correct point mutations with greater safety [8]. Prime editing, first described in 2019, combines CRISPR with reverse transcriptase, enabling the insertion or replacement of entire DNA fragments with remarkable precision [9]. It’s considered the most versatile tool yet — theoretically capable of introducing almost any change in the genome.

In 2025, prime editing crossed a historic milestone: it was applied experimentally in humans for the first time [10]. That May, Prime Medicine reported the first clinical results in a patient with chronic granulomatous disease (CGD). Nature described the achievement as the first-ever use of prime editing in humans [117].

The History and Milestones of CRISPR ⏳🧬

Although the CRISPR boom took off in the 2010s, the idea of editing genes has a much longer history. Back in the 1990s, researchers were already developing zinc-finger nucleases (ZFNs) — the first artificially designed “molecular scissors.” Around 2011, TALEN nucleases appeared, based on bacterial DNA-binding proteins. Both methods worked, but they were complex and expensive to design, which slowed their translation into medicine.

The true breakthrough came in 2012, when Emmanuelle Charpentier and Jennifer Doudna published their landmark paper showing that the bacterial CRISPR–Cas9 system could be repurposed as a tool to cut DNA at virtually any chosen site [1]. Independently, Feng Zhang’s team at the Broad Institute published similar results a few months later. This sparked not only a scientific race but also a fierce patent battle between the University of California and the Broad Institute over rights to a technology worth hundreds of millions of dollars. In the end, both sides secured parts of the patent portfolio, and biotech companies today license CRISPR from one or the other. The dispute itself underscored just how valuable — and hotly contested — the discovery had become.

Riding the wave of enthusiasm, the years 2013–2015 saw the birth of the first CRISPR-focused startups. In 2013, Editas Medicine was founded, co-initiated by Feng Zhang and genomics pioneer George Church. The following year, Intellia Therapeutics was launched with Jennifer Doudna as a co-founder, while in Switzerland, Emmanuelle Charpentier co-founded CRISPR Therapeutics. These three companies formed the first wave of CRISPR biotech and later debuted on NASDAQ, raising hundreds of millions of dollars from investors. Media attention exploded — CRISPR appeared in The New York Times, in popular magazines, and on science shows. The period was sometimes described as “CRISPR-mania,” with soaring expectations of miracle cures for cancer, HIV, genetic disorders, and beyond. 🌍

The first human clinical trials with CRISPR began in the mid-2010s. In 2016, a Chinese oncology team used CRISPR-edited immune cells in a patient with lung cancer — a pioneering but experimental attempt that was never widely reported [13].

The next leap came in 2019 in the United States, where researchers launched a clinical trial for sickle cell disease. Stem cells from patient Victoria Gray’s bone marrow were edited to produce healthy hemoglobin. Soon after, a similar approach was tested for beta-thalassemia, another severe blood disorder. That same year, Editas began a first-of-its-kind trial for Leber congenital amaurosis, a rare inherited blindness, injecting a CRISPR-based vector directly into the eye. This marked the first in vivo use of a gene editor in the United States. 👁️✨

In 2020, Intellia Therapeutics pushed the frontier further with the first systemic gene editing directly inside the body. In the NTLA-2001 trial, patients received nanoparticles carrying mRNA encoding CRISPR, which traveled to the liver and disabled the gene responsible for transthyretin amyloidosis — a fatal protein-folding disease. In 2021, it was announced that this one-time therapy reduced toxic protein levels by more than 80% [14]. The result was hailed as a breakthrough: the first proven success of systemic in vivo gene editing in humans.

Regulatory approvals soon followed. In November 2023, the UK’s MHRA became the first agency worldwide to approve Casgevy for sickle cell disease (SCD) and beta-thalassemia (TDT). The U.S. FDA followed, approving Casgevy for SCD on December 8, 2023, and for TDT on January 16, 2024. In the EU, the therapy received conditional approval on February 13, 2024 (for patients aged 12+). In the U.S., the list price for Casgevy was set at roughly $2.2 million, while Bluebird Bio’s alternative gene therapy Lyfgenia came in at around $3.1 million [2][3][116]. 💰💉

It took just eleven years to move from the first CRISPR publications to life-saving therapies. “Going from the lab to an approved treatment in only 11 years is truly an extraordinary achievement,” said Jennifer Doudna, reacting to the approval of Casgevy [16].

She also emphasized the symbolism: the first CRISPR therapy targets sickle cell disease — a condition long neglected by medicine, now offering hope of a cure to thousands of patients [17].

— One could say the era of gene-editing medicine has officially begun. Having proven that CRISPR can safely and effectively treat severe genetic disorders, the door is now wide open for its next applications.

Lulu and Nana — The Birth 🎉🤯

The road from an idea born in the lab to a therapy used in patients is never straightforward. For CRISPR, the path was marked not only by technical hurdles but also by profound ethical questions — where should science draw the line?

In 2018, the world learned the name He Jiankui. The Chinese researcher announced that he had edited the genes of human embryos — and that two girls, Lulu and Nana, had been born. In a short video posted online, he spoke of them almost as symbols of a new era, emphasizing that they were “as healthy as any other children.”

The first video in which He Jiankui announced the birth of Lulu and Nana

The goal of the experiment sounded simple enough: disable the CCR5 gene so that the girls would be resistant to HIV infection [11]. The problem was that CCR5 is not just a gateway for HIV — it’s also part of the immune system. Its absence can make people more vulnerable to other infections, like West Nile virus or even influenza. Scientists knew this all too well. That’s why, instead of admiration, He Jiankui’s announcement triggered a wave of condemnation.

A few days later, at a conference in Hong Kong, Jiankui faced a packed auditorium of researchers. What unfolded was not a scientific debate but a reckoning over responsibility and ethics. One attendee later remarked that the atmosphere felt like a trial — only this time, it was the scientific community delivering the verdict. ⚖️

His story became a warning. It underscored that a technology capable of rewriting the code of life demands not just knowledge and boldness, but boundaries. 🚧

And yet, despite the scandal, the field didn’t stall. The following years brought dozens of clinical programs aimed at patients suffering from severe, otherwise incurable genetic diseases. This time, however, researchers advanced step by step — with safety and ethics at the forefront, as if the memory of Lulu and Nana still hovered over every experiment.

The Gene Editing Landscape and Its Key Players 🗺️

The rapid rise of CRISPR has given birth to an entire biotech sector focused on genome editing. Below, we’ll look at the most important publicly traded companies in the field — their profiles, achievements, and the challenges they face.

Each has chosen its own strategy and therapeutic niche, but they all share the same central idea: using precise DNA editing as a way to treat disease. We’ll take a closer look at CRISPR Therapeutics, given its pioneering role, but also explore other major players shaping the field: Intellia, Editas, Beam, Caribou, along with newer entrants like Prime Medicine and Verve Therapeutics.

CRISPR Therapeutics — The Pioneer with the First Approved Therapy 📃🏆

Founded in 2013 by Emmanuelle Charpentier, CRISPR Therapeutics became the first company to bring a gene-editing therapy to market. Together with Vertex Pharmaceuticals, it developed exa-cel (marketed as Casgevy) for patients with sickle cell disease (SCD) and beta-thalassemia (TDT).

The approach is powerful but complex: stem cells are taken from the patient’s bone marrow, the BCL11A gene (which suppresses fetal hemoglobin production) is switched off using CRISPR, and the edited cells are transplanted back after conditioning therapy. The result? The body starts making healthy fetal hemoglobin instead of the faulty adult version [3][18].

The phase 3 results were groundbreaking:

• 93.5% of sickle cell patients were free from vaso-occlusive crises for a full year.

• 25 out of 27 beta-thalassemia patients became independent of blood transfusions [19][20].

This success led to regulatory approvals in 2023 [15], a milestone confirming that CRISPR could form the basis of safe and effective therapies [21]. 🚀

Expanding the Pipeline

Beyond exa-cel, CRISPR Therapeutics is building a broad portfolio, cementing its role as a leader in gene editing:

1. Oncology (CAR–T therapies)
Traditional CAR–T therapies use a patient’s own T cells (autologous). CRISPR Therapeutics is pioneering allogeneic CAR–T, using donor-derived T cells that are edited to remove rejection markers and enhanced to attack cancers more effectively [22][23].

• New generations like CTX112 (CD19) and CTX131 (CD70) include expanded edits (e.g. TGFBR2 and Regnase-1) to reduce T cell exhaustion and boost activity.

• Phase 1/2 trials are ongoing in lymphomas, leukemias (CD19), and solid tumors like kidney cancer (CD70) [30][31].

• Challenges remain (rejection, relapse [32][33]), but CRISPR’s iterative upgrades and streamlined manufacturing give it an edge.

2. Type 1 Diabetes
In partnership (later acquisition) with ViaCyte, the company is developing stem-cell–derived pancreatic cells edited with CRISPR to be “invisible” to the immune system, avoiding the need for lifelong immunosuppression [34][35]. Early trials are underway, with the ambitious goal of restoring natural insulin production — a potential functional cure for diabetes.

Strengths and Challenges

CRISPR Therapeutics’ biggest advantage is clear: it was the first to market a CRISPR therapy (exa-cel/Casgevy), giving it unmatched scientific and clinical credibility. The target market is significant — in the U.S. alone, ~100,000 people live with sickle cell disease, and globally beta-thalassemia affects tens of thousands more. Its partnership with Vertex provides financial backing, clinical expertise, and regulatory experience — critical for commercialization.

The company also benefits from a broad pipeline (rare diseases, oncology, diabetes) and access to key CRISPR patents(via Doudna/Charpentier licensing), securing its position as a cornerstone player in the field.

But challenges remain:

• Complex procedure: exa-cel requires a bone marrow transplant with intensive chemotherapy upfront [36][37].

• High cost: ~$2.2 million per patient [38].

• Accessibility: only specialized centers can deliver it, limiting near-term revenues.

• Payer negotiations: CRISPR and Vertex must persuade insurers and health systems that a one-time cure is more cost-effective than decades of chronic care [39].

• Competition: Bluebird Bio already won FDA approval for Zynteglo (beta-thalassemia, 2022) and Lyfgenia (sickle cell, December 2023), creating direct head-to-head battles [2][3].

This means CRISPR Therapeutics isn’t just competing with itself — it faces off against another cutting-edge platform: viral vector–based gene therapies. And the challenges aren’t only scientific. The financial picture remains tough. Despite its partnership with Vertex, the company — like most early-stage biotechs — has been running at a loss.

Across the biotech sector, investor pressure is mounting: cut costs, deliver profits faster. In 2023, CRISPR Tx reduced headcount by ~50 employees (~10%), and in 2025 announced another round of layoffs (numbers undisclosed). Management framed it as a focus on “key priorities” and greater operational discipline [40][41]. In reality, it’s part of a broader industry trend — capital markets are demanding higher efficiency and a leaner, more selective approach to pipelines.

In other words, the scientific revolution of CRISPR hasn’t yet translated into a financial breakthrough. Despite medical success, the company’s stock hasn’t soared as some once predicted. Shares of CRSP remain volatile, though as of mid-2025 the company still holds the leadership crown, with a market cap of around $6 billion — comfortably ahead of its competitors [42][43]. 🐎

Intellia Therapeutics — Editing Genes Inside the Body 🧬💉

Founded in 2014 with the involvement of Jennifer Doudna, Intellia Therapeutics set itself apart early on with a bold strategy. While most companies pursued ex vivo therapies (editing a patient’s cells outside the body, then transplanting them back), Intellia focused on the riskier but potentially transformative path of in vivo editing — rewriting genes directly inside the patient.

This approach eliminates the need for complex transplant procedures and opens the door to one-time therapies with broad potential [44].

The Platform: CRISPR Delivered by LNPs

Intellia built its platform around lipid nanoparticles (LNPs) — the same delivery vehicles that powered mRNA vaccines. These LNPs transport CRISPR’s toolkit (Cas9 mRNA + guide RNA) into the liver, which naturally acts as a “filter” for LNPs, making it the ideal first target [45].

NTLA-2001: ATTR Amyloidosis

The flagship program, NTLA-2001, is aimed at hereditary transthyretin amyloidosis (ATTR) — a disease caused by toxic buildup of misfolded TTR protein in nerves and the heart. Instead of fixing the mutation, the therapy shuts down the TTR gene entirely in liver cells, halting production of the harmful protein [46][47]

The results have been striking:

• A single IV infusion reduced TTR levels by >80% at low doses and >90% at higher doses [14][48].

• The effect has lasted for at least two years of follow-up, confirming durable genome editing [49].

For context: existing drugs only stabilize TTR or modestly reduce it — nowhere near this magnitude of reduction.

On safety, the therapy has shown a favorable profile: mostly mild infusion-related reactions, with serious events rare and manageable. That balance of risk and benefit helped Intellia secure FDA clearance to begin phase 3 trials in 2023 [50][51], with a large randomized study now underway [52]. If successful, NTLA-2001 could become the second CRISPR therapy ever approved, likely around 2026–2027.

NTLA-2002: Hereditary Angioedema (HAE)

Intellia’s second major program, NTLA-2002, targets hereditary angioedema (HAE) — a rare disease marked by recurrent, life-threatening swelling attacks. The strategy mirrors NTLA-2001: permanently disable the KLKB1 gene, which drives excessive inflammation.

Phase 1/2 results have been eye-opening:

• After a single CRISPR infusion, most patients experienced no further swelling attacks for months.

• Some were able to discontinue existing preventive medications without relapse [53][54].

• At the highest dose, the disease-causing protein dropped by ~90% within four months [55].

Crucially, no serious adverse events have been reported, and the therapy has been well tolerated. The FDA granted Orphan Drug and RMAT status, while EMA gave it PRIME designation [58]. — regulatory signals that highlight its promise. A global phase 3 trial is expected to launch in 2025 [56][57].

Other Programs & Partnerships

Beyond ATTR and HAE, Intellia and its partner Regeneron are testing CRISPR in hemophilia (to boost clotting factor production via liver editing), as well as in other metabolic and rare diseases. Oncology is on the radar, but Intellia has invested less aggressively in CAR–T than competitors, focusing instead on its in vivo strength.

Notably, Intellia has been a leader in developing systematic ways to monitor off-target effects. So far, no major issues have been seen in trials, suggesting CRISPR’s risks can be managed at acceptable levels.

Strengths

• Pioneer in in vivo editing — potentially the future of genetic medicine.

• Durable, one-time therapies — ATTR and HAE data show diseases can be silenced with a single infusion.

• Regulatory momentum — first-ever FDA greenlight for an in vivo CRISPR phase 3 trial [52],

• Delivery expertise — deep know-how with LNPs, a proven modality.

• Big partnerships — Regeneron and UC Berkeley licensing provide both resources and patent strength.

  ---

  🍒 ATTR (NTLA-2001): first successful systemic in vivo CRISPR editing in humans; durable >80–90% TTR reductions; phase 3 ongoing.

  🍒 HAE (NTLA-2002): single infusion largely eliminated swelling attacks; moving toward global phase 3 in 2025 with strong regulatory backing.

Weaknesses

• Long-term unknowns — permanently disabling genes raises questions about safety decades later (e.g. theoretical cancer risks from off-target edits). Patients will need lifelong monitoring.

• Commercial uncertainty — ATTR and HAE are rare diseases; success is promising but markets are smaller than broad-population conditions.

• Fierce competition — rivals like Beam (base editing) and Prime Medicine (prime editing) offer next-gen precision. Verve and others are also testing ATTR approaches.

• Investor fatigue — despite breakthrough clinical data, Intellia’s stock dropped sharply in 2022–23, as investors realized revenues are still years away.

By mid-2025, Intellia’s market cap was about $1.2 billion — far below CRISPR Therapeutics, despite its breakthrough clinical results [42][43]. The message is clear: the market still values its future revenues cautiously. Global phase 3 trials, plus the manufacturing and commercialization that follow, will likely require substantial capital. That could mean more partnerships or additional equity raises — adding pressure on investors. 💸

From a scientific perspective, the company also faces a major challenge: delivering CRISPR beyond the liver. Lipid nanoparticles (LNPs) work beautifully in the liver, which naturally traps them through the reticuloendothelial system. But to edit genes in the lungs, brain, or muscles, new solutions will be needed — alternative vectors or redesigned LNP chemistry. Intellia is actively investing in this area, though it remains early-stage research.

Despite these hurdles, Intellia remains firmly among the top tier of gene-editing companies. Its programs continue to generate excitement across both the scientific community and patient advocacy groups. 🌍✨

Editas Medicine — From Eyes to Blood: The Race to Catch Up 👁️🚡🩸

Founded in 2013 with an A-list roster — Feng Zhang, George Church, and initially Jennifer Doudna (who later moved to Intellia) — Editas Medicine was one of the first CRISPR companies. With early access to Broad Institute patents (via Zhang), the company initially held a legal edge in using Cas9 for human genome editing.

The First Bet: Eye Diseases (EDIT-101)

Editas’ first target was Leber congenital amaurosis type 10 (LCA10), a genetic eye disease caused by mutations in the CEP290 gene. Its candidate, EDIT-101, was designed to directly edit the gene in retinal cells, delivered by a CRISPR vector injected under the retina.

In 2019, Editas carried out the first-ever in vivo CRISPR treatment in the U.S., dosing human patients. Over the following years, a small group received varying doses. By 2021–2022, results showed only modest improvements: some patients reported better light sensitivity or peripheral vision, but effects were inconsistent and hard to conclusively attribute to the therapy [59].

Safety was acceptable — no major issues reported — but the lack of clear efficacy led Editas to seek a partner for further development [60], while it shifted resources toward blood diseases.

A Pivot to Blood Disorders (EDIT-301)

Parallel to its eye program, Editas was developing a hematology strategy using a different enzyme: Cas12a (Cpf1). Unlike Cas9, Cas12a cuts DNA differently, leaving “sticky ends” and targeting different sequences.

Their therapy, EDIT-301, edits the BCL11A gene in blood stem cells, boosting fetal hemoglobin (HbF) to counter sickle cell disease (SCD) and beta-thalassemia. Results from phase 1/2 studies (RUBY and EDITHAL) have been very strong:

• In 11 SCD patients, all achieved high HbF levels and none experienced vaso-occlusive crises post-treatment [61].

• In 6 beta-thalassemia patients, all became transfusion-independent [62].

• Follow-up lasted at least 5 months (longer for some), with no serious adverse events linked to the therapy.

The FDA granted Orphan Drug and RMAT status [63]. If results hold in larger groups, EDIT-301 could make Editas a credible competitor to CRISPR Therapeutics in blood diseases.

Strategic Shifts

EDIT-301’s success is critical for the company’s survival. Editas has undergone significant restructuring: a CEO change, staff cuts, and program prioritization. Costly, uncertain projects like EDIT-101 were deprioritized, while resources were refocused on hematology.

The company is also exploring oncology:

• With Bristol Myers Squibb, Editas is testing T-cell editing.

• Independently, it’s studying natural killer (NK) cell editing.
  Both are early-stage efforts.

Strengths

• Cas12a advantage: first to bring this nuclease into the clinic. Cas12a’s distinct cutting style could be superior in certain indications [61].

• Flexibility: ability to deploy both Cas9 and Cas12a expands its scientific toolkit.

• Strong patent portfolio: especially tied to the Broad Institute, giving Editas legal freedom to operate.

• Survival and focus: after restructuring, the company has streamlined toward its most promising asset, EDIT-301.

• Market opportunity: with a market cap of only ~$400–500M in 2025, Editas could be an attractive acquisition target — or deliver outsized returns if EDIT-301 succeeds.

Weaknesses

• Lost ground: years of falling behind rivals and underwhelming EDIT-101 results damaged credibility.

• Single-point dependency: current leadership has bet everything on EDIT-301 — a high-risk, high-reward strategy.

• Weak partnerships: unlike CRISPR Therapeutics (Vertex) or Intellia (Regeneron), Editas lacks a strong late-stage partner.

• Financial strain: phase 3 trials will require significant funding, likely needing new partners or equity raises.

• Brand perception: Editas doesn’t carry the same investor trust or “hype factor” as CRISPR Tx or Intellia.

Outlook

If EDIT-301 continues to deliver strong results, Editas could stage a comeback and reassert itself among CRISPR’s frontrunners. But with limited resources, no major commercial partner, and intense competition, the company is operating on thin ice.

For now, Editas remains a company with big scientific promise (Cas12a, EDIT-301) but a fragile financial and strategic position. Whether it reclaims a leading role — or becomes an acquisition target — depends almost entirely on the success of EDIT-301.

Conclusion to Part I 👨🏻‍🍳

Editas, Intellia, and CRISPR Therapeutics ushered in the era of gene-editing commercialization. They proved that CRISPR–Cas9 is not only a scientific breakthrough but also a foundation for entirely new business models. Their rapid growth and public market debuts drew the eyes of the entire biotech industry — along with hundreds of millions of dollars in funding.

But this is only the beginning of the story. In Part II, we’ll turn to the next wave of players joining the race. We’ll also dive into the latest clinical results from 2023–2025 and explore the challenges that could determine whether gene editing becomes a lasting pillar of modern medicine.

🧬

📚 Selected References

· U.S. Food and Drug Administration – press release on the approval of the first CRISPR therapy (Casgevy) for sickle cell disease [2][3].

· Innovative Genomics Institute, CRISPR Clinical Trials: A 2024 Update – overview of ongoing CRISPR trials, including results in SCD/TDT, ATTR, HAE, and CAR-T [111][48][53][70].

· STAT News, Jason Mast, The CRISPR companies are not OK (2025) – analysis of the sector’s challenges and the gap between scientific breakthroughs and financial success [1][40].

· Nanalyze, When Will Gene Editing Stocks Finally Take Off? (2025) – examination of correlations and valuations across gene-editing companies [109][43].

· Nature News, Heidi Ledford, World first: ultra-powerful CRISPR treatment trialled in a person (2025) – coverage of the first use of prime editing in a human patient [9][10].

· The Guardian, Ian Sample, Chinese scientist who edited babies’ genes jailed for three years (2019) – report on He Jiankui’s case and its ethical fallout [11][12].

· Fierce Biotech, James Waldron, Graphite’s hopes for sickle cell ‘cure’ blunted after first patient dosed experiences serious event (2023) – report on Graphite Bio’s halted trial [103].

· U.S. FDA – background on indications and mechanism of action for Casgevy and the parallel lentiviral therapy (Lyfgenia) [2][3].

(Sources: high-reputation English-language publications with up-to-date scientific and financial data as of August 2025.)

📖 References

[1] [40] [59] The CRISPR gene editing revolution loses its mojo. STAT News. (Feb 2025). Link

[2] [3] [4] [5] [18] [116] FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. FDA Press Release. (Dec 2023). Link

[6] [7] CRISPR Illustration. National Institute of General Medical Sciences. Link

[8] [13]–[15], [19]–[21], [22]–[39], [41], [44]–[49], [50]–[58], [61]–[63], [64]–[111] CRISPR Clinical Trials: A 2024 Update. Innovative Genomics Institute. (2024). Link

[9] [10] Ledford H. World first: ultra-powerful CRISPR treatment trialled in a person. Nature. (2025). Link

[11] [12] Sample I. Chinese scientist who edited babies’ genes jailed for three years. The Guardian. (Dec 2019). Link

[42] [43] [79] [109] When Will Gene Editing Stocks Finally Take Off? Nanalyze. (Jul 2025). Link

[60] Editas, changing course again, looks to partner lead CRISPR therapy. BioPharma Dive. (2024). Link

[103]–[106] Waldron J. Graphite’s hopes for sickle cell ‘cure’ blunted after first patient dosed experiences serious event.Fierce Biotech. (2023). Link

[110] Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data. ASCO Annual Meeting. (2024). Link

[111] Exploring FDG PET + MRI for multiple myeloma staging. J Clin Oncol. ASCO (2024). Link

[112] [113] [115] Caribou Biosciences Reports Q2 2025 Results and Pipeline Update. Caribou Investor Relations. (Aug 2025). Link

[114] CB-010 (ANTLER trial) clinical update. J Clin Oncol. ASCO (2024). Link

[117] Prime Medicine announces breakthrough clinical data (PM359, CGD). Prime Medicine Investor Relations. (2025). Link